Pricing Log in Create free account
Friday 6 November 2026 Export NTRA’s income statement to Excel — free account

Natera, Inc.

NTRA Healthcare Diagnostics & Research

Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024.

Revenue
+34.1%
EPS
+34.4%
Free cash flow
−85.8%
Total debt
−0.06%

Quarter to September 2026, against a year earlier

315.62 48.14 −13.23%
Market cap
$52.4B
P/E
0.0×
Fwd P/E
−289×
Dividend yield
—
F-score
6/9
Altman Z
26.84
Beneish M
−2.17
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Natera, Inc. 10-Q filed Nov 5, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:49 PM ET · Document on sec.gov · Filing index

Red flags

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 7, 2026: 2 added · 2 removed · 22 modified; 22 with only figures updated

  1. Modified · Overview

    During the sixnine months ended JuneSeptember 30, 2026, we processed approximately 2,056,8003,150,600 tests, comprised of approximately 2,028,6003,109,500 tests accessioned in our laboratory, compared to approximately 1,708,2002,601,900 tests processed, comprised of approximately 1,680,1002,559,800 tests accessioned in our laboratory, during the sixnine months ended JuneSeptember 30, 2025. This

25 more changes in this Item, word by word, in Powerpack.